The global burden of cancer continues to rise, increasing the demand for effective and accessible oncology treatments. Eribulin Mesylate 0.5mg/ml Injection is an advanced chemotherapy medication widely used for treating metastatic breast cancer and advanced liposarcoma in patients who have previously undergone chemotherapy.
Cordium Pharmaceuticals Pvt Ltd is a trusted Indian pharmaceutical exporter supplying high-quality oncology medicines to hospitals, cancer centers, distributors, and healthcare procurement agencies worldwide.
As healthcare systems expand in Africa, Asia, the Middle East, Europe, and North America, the demand for reliable oncology medicine exporters has never been higher.
What is Eribulin Mesylate 0.5mg/ml Injection?
Eribulin Mesylate is an anti-cancer medication belonging to the microtubule dynamics inhibitor class.
It is indicated for:
- Metastatic Breast Cancer (MBC)
- Unresectable or Metastatic Liposarcoma
- Patients previously treated with anthracycline and taxane chemotherapy
This innovative therapy helps slow cancer progression and improve patient survival outcomes.
Diseases Treated with Eribulin Mesylate Injection
Metastatic Breast Cancer
Metastatic breast cancer occurs when cancer spreads beyond the breast tissue to organs such as:
- Liver
- Lungs
- Bones
- Brain
Eribulin is often recommended after prior chemotherapy treatments have become ineffective.
Advanced Liposarcoma
Liposarcoma is a rare cancer affecting fatty tissues. Eribulin has shown significant benefits in prolonging survival for eligible patients.
How Eribulin Mesylate Works
Eribulin disrupts the internal structure of cancer cells.
Mechanism of Action:
✔ Blocks microtubule growth
✔ Prevents cancer cell division
✔ Inhibits tumor progression
✔ Reduces disease spread
✔ Supports improved overall survival
Key Benefits of Eribulin Mesylate 0.5mg/ml Injection
- Effective for advanced-stage cancers
- Recommended after prior chemotherapy failure
- Clinically established treatment option
- Supports longer progression-free survival
- Used globally in oncology treatment protocols
- Administered under specialist supervision
Administration & Dosage Information
Strength: 0.5mg/ml
Route: Intravenous (IV)
Prescription: Strictly administered by oncology specialists.
Treatment schedules vary depending on:
- Body surface area
- Previous cancer therapies
- Kidney function
- Liver function
- Overall patient condition
Disclaimer: Dosage must only be determined by qualified healthcare professionals.
Common Side Effects
Some patients may experience:
- Fatigue
- Hair loss
- Nausea
- Decreased appetite
- Peripheral neuropathy
- Low white blood cell count
- Weakness
- Constipation
Medical monitoring throughout treatment is essential.
Why Global Buyers Choose Cordium Pharmaceuticals Pvt Ltd
Cordium Pharmaceuticals Pvt Ltd is dedicated to strengthening global cancer care through dependable pharmaceutical exports.
Our Export Strengths
✅ Quality-assured oncology medicines
✅ WHO-GMP compliant manufacturing network
✅ International export documentation support
✅ Temperature-controlled supply chain
✅ Bulk quantity availability
✅ Timely shipments worldwide
✅ Competitive export pricing
✅ Distributor partnership programs
✅ Long-term supply agreements
Countries We Serve for Oncology Medicine Export
Africa
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇿🇦 South Africa
Southeast Asia
🇵🇭 Philippines
🇻🇳 Vietnam
Middle East
🇦🇪 UAE
🇸🇦 Saudi Arabia
Central Asia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
International Markets
🇺🇸 USA
🇬🇧 UK
Why Demand for Eribulin Mesylate is Increasing Worldwide
Several factors are driving global demand:
Kenya, Nigeria & Ghana
- Rising breast cancer awareness
- Expansion of oncology hospitals
- Increased access to cancer treatments
Philippines & Vietnam
- Growing investment in advanced healthcare infrastructure
- Higher adoption of modern oncology therapies
UAE & Saudi Arabia
- Strong pharmaceutical import markets
- Demand for premium cancer treatment options
Uzbekistan & Kazakhstan
- Healthcare modernization initiatives
- Improved oncology screening programs
USA, UK & South Africa
- Need for diversified and dependable pharmaceutical supply chains
